HighTide Therapeutics, Inc. (02511) presented its monthly return for the period ended 28 February 2026. According to the announcement, the authorized share capital remains at 1,000,000,000 ordinary shares, each with a par value of USD 0.0001, maintaining a total of USD 100,000. The issued share count stands at 571.33 million shares with no treasury shares, reflecting no change from the preceding month.

The announcement also confirms compliance with the 25.00% public float threshold, and no share options, warrants, convertible instruments, or other arrangements were noted during the reporting period.